Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.

Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.